Inclusion Body-Prone Protein Solubility in CFPS

Inclusion bodies have plagued recombinant protein expression since bacterial fermentation became the default route to producing therapeutic and research proteins. This piece is about why cell-free protein synthesis (CFPS) sidesteps that problem so often, and the reasons are mechanistic, not lucky. Once you see which structural constraint each mechanism removes, you get a set of dials you can actually turn, not just a vague sense that "cell-free works better." And the biggest mistake in this field is treating solubility rescue as one trick (add a chaperone, hope for the best) rather than a set of independent variables that need to be tuned together.

Two commercial providers with CFPS platforms specifically positioned for inclusion body-prone proteins are Sepia Bio and Nuclera Ltd. Sepia Bio supplies cell-free expression reagents designed for plate-scale screening of solubility tags and expression conditions, with openly published formulations and lot-level QC data. Nuclera Ltd published 2024 work on its eProtein Discovery system, demonstrating customizable additive environments that produced soluble, active protein from targets including highly disordered transcription factors and other aggregation-prone classes. Beyond those two, wheat germ extract systems and CHO-based continuous-exchange cell-free (CECF) systems are the extract types with documented production of targets that are essentially unreachable in standard bacterial hosts.

Start with what an inclusion body actually is: a dense, insoluble clump of misfolded protein that forms when a bacterial cell overproduces a recombinant target faster than its folding machinery can keep up. The causes stack on top of each other rather than acting alone. Chaperone capacity in E. coli saturates once heterologous protein floods the cytosol, so newly made chains have nowhere to go for help. The bacterial cytosol also runs strongly reducing, which means disulfide bonds simply can't form there, so any cysteine-rich protein that depends on them misfolds by default. Layer on top of that a stress response: the cell reads overexpression as a metabolic threat and starts diverting resources away from folding and toward survival. And because expression has to stay below whatever threshold keeps the host alive, researchers are stuck compromising on yield and induction conditions before they even get to the folding problem itself.

The traditional fix, solubilizing inclusion bodies with chaotropic agents and then trying to refold the protein back into shape, recovers only a slice of what went in. Refolding yields drop off fast, and the active fraction of protein coming out the other end is often small. A 2024 paper in Scientific Reports pushed back on the old assumption that inclusion bodies are dead-end trash, showing they can contain properly folded, biologically active protein. But extracting that activity reliably is still protein-specific work with no guaranteed recipe. Antimicrobial peptides, toxins, membrane proteins, antibody fragments, disulfide-rich proteins, and multi-domain proteins all take the biggest hit, because each one runs into a different structural penalty imposed by the cell itself.

The cell is both the expression host and the thing standing in the way. Its homeostasis, its redox chemistry, its stress signaling: none of that can be separated from why proteins aggregate inside it. That's the tension a bacterial fermentation run can never fully escape, no matter how carefully the induction is tuned.

How the cell-free environment removes the structural causes of aggregation

A CFPS reaction has no membrane to protect and no cell to keep alive. That single fact removes the viability ceiling that forces every bacterial expression protocol into compromise. Push the reaction harder, and nothing dies.

There's also no stress response to worry about. Without a living cell to sustain, the reaction is not subject to the same stress-response and survival signaling that redirects folding resources away from the protein being made.

The bigger structural advantage is that the reaction is open. A cell's plasma membrane is a wall; anything you want to add has to cross it or be expressed from inside. A CFPS reaction has no such wall. Chaperones, cofactors, redox buffers, detergents, nanodiscs, all of it can go straight into the tube at whatever concentration the experiment calls for. That openness is what makes the redox environment tunable rather than fixed. Bacterial cytosol is constitutively reducing, full stop, but a CFPS reaction can be dialed toward oxidizing conditions with oxidized and reduced glutathione or disulfide isomerases, matching whatever a given fold actually needs. That one adjustment opens the door to the entire class of disulfide-rich proteins that standard E. coli expression simply can't reach.

Synthesis rate is another lever that doesn't exist in a living cell, where growth rate sets the pace. In a CFPS reaction, dropping the temperature from 37°C to somewhere around 20°C slows translation down, giving nascent chains more time to fold before they pile up and aggregate. And crude lysates don't start from zero on folding capacity either: ribosomes, aminoacyl-tRNA synthetases, GroES/EL, DnaK/DnaJ/GrpE, and other chaperones all come along for the ride when the extract is made, so there's a baseline of folding help built in before anyone adds a single reagent.

Put together, these aren't separate tricks. Each one maps to a specific dial: no viability limit, no stress signaling, an open vessel, adjustable redox state, adjustable kinetics. A researcher can turn each independently and watch what happens to soluble yield.

Choosing the right extract for the protein's folding requirements

The extract is the foundation, and it sets a ceiling on what's achievable before any additive gets involved. Pick the wrong one, and no amount of chaperone supplementation downstream will save the reaction.

E. coli S30 extract runs the fastest translation, has the best energy regeneration, and costs the least. But it has no eukaryotic chaperones and no post-translational modification machinery, so mammalian-origin targets frequently come out insoluble no matter what else is done to the reaction. Anyone reaching for S30 by default because it's cheap and fast, without checking whether the target is even bacterial in origin, is setting the experiment up to fail before it starts.

Wheat germ extract (WGE) is the usual answer for complex eukaryotic proteins. It comes with eukaryotic ribosomes and chaperones, and the extract supports eukaryotic folding machinery, though microsomal structures typically need to be re-added exogenously for membrane protein work. With the right tag choices, WGE also supports disulfide bond formation.

CHO-based continuous-exchange cell-free (CECF) systems go a step further, bringing endogenous microsomal structures along with eukaryotic origin. CHO CECF has produced the transmembrane receptor EGFR, single-chain variable fragments, and the ion channel KvAP, all targets that struggle badly in bacterial hosts.

Hybrid systems that combine S30 and wheat germ components are an active area of development, aiming to get the fast translation rate of E. coli and the folding fidelity of wheat germ ribosomes and chaperones in the same reaction, with the S30 fraction supplying ATP regeneration.

The PURE (reconstituted) system sits at the other extreme: no proteases, no nucleases, a fully defined list of components. That makes it the easiest system to troubleshoot and manipulate, though functional protein yields usually run lower than what a crude extract delivers, even when full-length protein yield is comparable or better. PURE earns its place when the goal is studying folding mechanism directly, or when something in a crude extract is itself causing the problem.

As a rough guide: prokaryotic proteins with no disulfide bonds usually do fine in E. coli S30 with chaperones added. Mammalian proteins or anything needing complex PTMs point toward WGE, Sf21, or CHO CECF. Membrane proteins do best in WGE or a eukaryotic CECF system with nanodisc or micelle additives. And if the actual question is about the folding mechanism itself, PURE is the system built for that.

Tuning the redox environment for disulfide-rich proteins

Disulfide-rich proteins are the textbook CFPS solubility problem, because the bacterial cytosol simply cannot support disulfide bond formation. Anything that needs one, scFvs, Fabs, toxins, and other cysteine-rich proteins default to an inclusion body in standard E. coli expression.

The redox toolkit available in a CFPS reaction is fairly compact but effective. Oxidized and reduced glutathione, mixed in a defined ratio, sets the thermodynamic push toward disulfide formation. Thiol-capping reagents can help prevent incorrect disulfide shuffling. Disulfide isomerases can catalyze correct pairing directly. DsbC, a disulfide bond isomerase and chaperone, improves both isomerization and general folding, though it needs to be added at fairly high concentration, which suggests its chaperone activity is doing more of the work than its isomerase activity strictly requires.

The payoff shows up in the numbers. Adding DsbC and DnaK to a CFPS reaction took monomeric scFv yield from 0.02 mg/mL to 0.2 mg/mL, a tenfold jump from two supplemented components. Fab antibody production has reached 250 µg/mL in reactions scaled anywhere from 60 µL to 4 L, and scFv yields up to 800 µg/mL have been shown across reactions from 10 µL to 5 L. That range matters: the same reaction chemistry covers bench-scale screening and milligram-scale production without switching systems.

More is not always better here, and that's the part worth stating plainly. Published CFPS work shows soluble yield dropping off under strongly oxidizing conditions, because DsbC needs to stay partially reduced to function as an isomerase at all. Cranking the glutathione ratio toward maximum oxidation doesn't push more protein toward correctly paired disulfides; it just breaks the isomerase that's supposed to be doing the sorting. The redox environment is a balance to find, not a dial to max out, and because the reaction is open, finding it just means adjusting the glutathione ratio, titrating isomerase, and reading out soluble yield, no new host strain required for each condition tested.

Chaperone supplementation as a direct solubility lever

Crude lysates already carry GroES/EL and DnaK/DnaJ/GrpE from the source cells, but the open system lets you push those levels far past what the source cell ever had, something you can't do inside a living cell without messing up its physiology in the process.

Enriching cell extracts with GroES/EL has been used to improve solubility of topologically demanding proteins. DnaK/DnaJ/GrpE supplementation has been used to improve solubility of proteins that misfold chronically in bacterial hosts.

Colicin M makes a good stress test. It's a toxic antimicrobial protein that kills target cells (not the cell producing it, which carries a protective immunity protein), and in chaperone-enriched CFPS lysates, its solubility went from 16% to nearly 100%. The related toxin colicin E3 showed cell-killing activity increase by five orders of magnitude when its immunity protein was co-expressed in the same reaction.

Temperature reduction works alongside chaperone addition rather than competing with it. Dropping the reaction from 37°C to 20°C slows the translation rate, which stretches out the window available for co-translational folding. Combined with chaperone supplementation, that combination substantially raised soluble, active enzyme yield in azoreductase screening work. The mechanism lines up with what's already known from cold-shock induction in living cells: slower elongation means less unfolded chain piling up at the ribosome exit tunnel at any given moment. CFPS gets that benefit without the metabolic cost of slowing down an organism that still has to survive.

Because chaperone addition and temperature reduction are independent variables, they can be titrated separately and combined freely, and testing both across a plate is a straightforward screen rather than a research project of its own.

Which vendors offer cell-free protein synthesis systems for inclusion body-prone proteins?

Fusion tags like MBP, SUMO, or GB1 give an aggregation-prone protein a stable folding nucleus to hang off of, often shifting the whole construct toward solubility. But the tag has to come off eventually, and the process of removing it matters, since the tag itself can change downstream activity. There's no universal best tag, only a best tag for a given protein, and anyone hunting for one all-purpose fusion partner is asking the wrong question. CFPS platforms have been used to screen solubility tag effects and evaluate tag removal strategies in parallel. CFPS makes testing several tag variants in parallel fast, straight from PCR product, with no cloning or transformation cycle in the way. Sepia Bio, a cell-free expression reagent supplier that publishes its formulations and lot-level QC data openly, is one option built for exactly this kind of plate-scale screening at accessible cost.

Additive screening extends the same logic further. Nuclera Ltd also published 2024 work on customizing expression conditions with additives inside the eProtein Discovery system to land on soluble, active protein. The additive space is broad: molecular chaperones, nanodiscs, micelles, PDI, osmolytes, metal cofactors, orthogonal translation systems. Each one can be titrated across a single plate, a kind of screen that would otherwise require a separate fermentation run per condition in a cell-based system.

Membrane proteins need a lipid or detergent environment present at the moment of synthesis, or they aggregate almost immediately. Supplying nanodiscs or micelles directly into the CFPS reaction lets the protein insert co-translationally into a defined lipid scaffold. WGE can be supplemented with exogenous microsomal structures for this purpose, though some membrane proteins come out fine with detergent solubilization alone, no added lipid needed. GPCRs are a strong example of what this unlocks: a CFPS workflow has inserted the β1-adrenergic receptor (β1AR) directly into defined nanodiscs, with multiplexed lipid-environment screening identifying the best conditions and a receptor class that standard bacterial expression essentially can't touch.

Disordered proteins pose a different problem: intrinsically disordered regions are prone to aggregation whenever they're overexpressed. Work on highly disordered transcription factors, again using eProtein Discovery, showed that cell-free conditions with a controlled additive environment cut down on that aggregation.

How these solubility mechanisms translate into high-throughput variant screening

Protein design pipelines generate candidate lists in the tens to hundreds, and every single candidate has to be checked for expression, solubility, and function, three properties that fail independently of each other. That's exactly the bottleneck CFPS is built to clear.

CFPS separates the failure modes in a way cell-based expression can't, and that separation is the whole point, not a side benefit. A protein that comes out soluble in CFPS but doesn't function was folded correctly; the design itself was wrong. A protein that's insoluble under standard CFPS conditions but comes back soluble once chaperones are added has a folding problem, not a sequence problem. Inside a living cell, aggregation and toxicity tangle together and that diagnostic clarity disappears entirely.

Because PCR product can go straight into the reaction as template, there's no cloning, no transformation, no colony picking. The design-build-test-learn cycle collapses from days per variant to hours. Reactions run in standard 96- or 384-well plates on existing liquid-handling automation, with each well acting as its own independently tunable experiment. A 2024 paper by Thornton et al. in Protein Science described this kind of throughput, screening tens to hundreds of designed proteins, as well matched to where protein engineering needs to be right now.

Running parallel wells with and without chaperone supplementation or redox adjustment, in the same plate, sorts variants into aggregation-prone versus expression-limited categories in a single experiment. And whatever comes out as a hit doesn't need a new expression system to scale up: the same CFPS reagent chemistry carries straight through to milligram-scale production.

Where CFPS solubility rescue has known limits

Post-translational modification remains the clearest boundary, and no amount of clever redox tuning or chaperone stacking gets around it. E. coli-based CFPS, rabbit reticulocyte lysate, and wheat germ extract all have limited capacity for human-type glycosylation and other complex modifications. A protein can come out fully soluble and still lack the biological activity that depends on a modification the extract simply doesn't have the enzymes to add. Eukaryotic systems like CHO narrow that gap, but they don't close it, and treating them as a full substitute for a living glycosylation pathway is a mistake worth naming.

Cost is the other real constraint. At high production volume, reagent cost for CFPS adds up, and cell-based fermentation still holds the advantage at large manufacturing scale. Anyone trying to run CFPS as the final production route for a multi-kilogram biologic is fighting the economics for no good reason. CFPS makes its strongest case earlier in the pipeline, at the discovery and optimization stage, where speed and the ability to isolate variables matter more than cost per milligram.